COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,788 Articles (22,523 medRxiv, 8,265 bioRxiv)

Most recent first Previous |  Page 2895: Articles 28941-28950  | Next

The Easter and Passover Blip in New York City
Vierlboeck, M., Nilchiani, R. R., Edwards, C. M.
10.1101/2020.04.14.20065300 — Posted: 2020-04-17
Countries should aim to lower the reproduction number R close to 1.0 for the short-term mitigation of COVID-19 outbreaks
Hochberg, M. E.
10.1101/2020.04.14.20065268 — Posted: 2020-04-17
Model calibration, nowcasting, and operational prediction of the COVID-19 pandemic
Annan, J. D., Hargreaves, J. C.
10.1101/2020.04.14.20065227 — Posted: 2020-04-17
Optimal Allocation of COVID-19 Test Kits Among Accredited Testing Centers in the Philippines
Buhat, C. A. H., Duero, J. C. C., Felix, E. F. O., Rabajante, J. F., Mamplata, J. B.
10.1101/2020.04.14.20065201 — Posted: 2020-04-17
Refined compartmental models, asymptomatic carriers and COVID-19
Oliveira, G.
10.1101/2020.04.14.20065128 — Posted: 2020-04-17
Novel Coronavirus in Nigeria: Epidemiological analysis of the first 45 days of the pandemic
Adegboye, O., Adekunle, A. I., Gayawan, E.
10.1101/2020.04.14.20064949 — Posted: 2020-04-17
Estimating the last day for COVID-19 outbreak in mainland China
Griette, Q., Liu, Z., magal, p.
10.1101/2020.04.14.20064824 — Posted: 2020-04-17
Estimate of Covid-19 prevalence using imperfect data
Rudnicki, W. R., Piliszek, R.
10.1101/2020.04.14.20064840 — Posted: 2020-04-17
What influences COVID-19 infection rates: A statistical approach to identify promising factors applied to infection data from Germany
Mercker, M., Betzin, U., Wilken, D.
10.1101/2020.04.14.20064501 — Posted: 2020-04-17
Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-qPCR
Smyrlaki, I., Ekman, M., Vondracek, M., Papanicoloau, N., Lentini, A., Aarum, J., Muradrasoli, S., Albert, J., Högberg, B., Reinius, B.
10.1101/2020.04.17.20067348 — Posted: 2020-04-17 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).